Τσιατάς Μαρίνος, Παθολόγος Ογκολόγος

1994: BSc Βιολογίας, Σχολή Θετικών Επιστημών, Πανεπιστήμιο Αθηνών

2000: MD. Ιατρική Σχολή Αθηνών

2001: PhD. Ανοσολογία, Πανεπιστήμιο Αθηνών, Τμήμα Βιολογίας

2011: Πιστοποίηση από την Εταιρεία Ογκολόγων- Παθολόγων Ελλάδας

2014: Πιστοποίηση από την Ευρωπαϊκή Εταιρεία Ιατρικής Ογκολογίας

• 1992-1994: Graduate Research Assistant, Diploma Thesis on thymosins (Department of Biology, University of Athens).
• 1995-2000: Post-graduate Research Assistant, Doctoral Thesis on immunological properties of cytokines in cytotoxicity and antigen presentation models. PhD. . (Department of Biology, University of Athens, Supervisor: Prof. T. Patargias, in collaboration with the Cancer Immunology and Immunotherapy Center, Savvas” Cancer Hospital).
• 2003-2010: Post-doctoral Fellow and Research Associate, Department of Clinical
• Department of Clinical Therapeutics, “Alexandra Hospital”, School of Medicine, University of Athens.
• 2010-2011: Visiting Research Scholar, Ovarian Cancer Research Center (Prof. Dr. George Coukos), Abramson Cancer Center, School of Medicine, University of Pennsylvania, USA (Hellenic Society of Medical Oncology Scholarship)
• 2011-2013: Senior Research Associate, Immunology Lab, Department of Biology, University of Athens
• 2011-present: Medical Oncologist, Athens Medical Center
• 2013-2019: Medical Advisor in Oncology/Hematology, Janssen Pharmaceutical Companies of Johnson &Johnson, Greece

• 2007-2010: Instructor in post-graduate programs (Masters) of the Department of Biology “Biological Applications in Medicine” and “Clinical Biochemistry-Molecular Diagnostics”, in colaboration with Medical School of the University of Athens, Greece
• 2012-2013: Instructor in Greek Academy of Oncology CME program (Section of Gynecologic Cancers)

• PI in CA209-8Y8 Phase IIb Trial: “A Phase 3b, Randomized, Doubel-blind Study of Nivolumab Combined with Ipilimumab versus Nivoluamab Monotherapy for Patients with Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- or Poor-Risk Factors”
• PI in CA045-009 Phase III Trial: ” A Phase 3, Randomized, Study of neoadjuvant and Adjuvant Nivolumab Plus NKTR-214, Versus Nivolumab Alone Versus Standard of Care in Participants with Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible”
• PI in DS8201-A-U303 Phase III Trial: “A Phase 3, Multicenter, Randomized, Open-label, Active Controlled Trial of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC), Versus Treatment of Physician’s Choice for HR positive, HER2-low Expressing, Unresectable and/or Metastatic Breast Cancer Subjects
• PI in DANUBE Phase I Trial: “A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First- Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination With Tremelimumab Versus Standard of Care Chemotherapy in Patients With
• PI in IMbassador250 Phase III trial: “A Phase ,3 Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide Versus Enzalutamide Alone in Patients With Metastatic Castration-Resistant Prostate Cancer After Failure of an Androgen Synthesis Inhibitor and Failure of, Ineligibility for, or Refusal of a Taxane Regimen”
• PI in Javelin Bladder 10 Phase I trial: ” A Phase 3, Multicenter, Multinational, Randomized, Open-Label, Parallel-Arm Study Of Avelumab (MSB0010718C) Plus Best Supportive Care Versus Best Supportive Care Alone As A Maintenance Treatment In Patients With Locally Advanced Or Metastatic Urothelial Cancer Whose Disease Did Not Progress After Completion Of First-Line Platinum-Containing Chemotherapy”
• PI in PRONOUNCE Phase I Trial: “A Multi-Center, Randomized, Assessor- Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients With Prostate Cancer and Cardiovascular Disease Receiving Degarelix (Gonadotropin-Releasing
• Hormone (GRH) Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist)”
• PI in PIVOT-10 Phase I Trial: “A Phase 2, Single-Arm Study Of Bempegaldesleukin (NKTR-214) In Combination With Nivolumab In Cisplatin Ineligible, Locally Advanced Or Metastatic Urothelial Cancer Patients”
• PI in IMMU-132-13 Phase III Trial: “A Randomized Open-Label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer” – PI in IMMU-132-06 Phase I Trial: “A Phase 2 Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer”
• PI in CONTACT-03 Phase I Trial: “A Phase 3, Multicenter, Randomized, Open-Label Study To Evaluate The Efficacy And Safety Of Atezolizumab Given In Combination With Cabozantinib Versus Cabozantinib Alone In Patients With Inoperable, Locally Advanced, Or Metastatic Renal Cel Carcinoma Who Experienced Radiographic Tumor Progression During Or After Immune Checkpoint Inhibitor Treatment”
• PI in MORPHEUS-UC Phase Ib/II Trial: A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatments And Combinations In Patients With Urothelial Carcinoma (MORPHEUS-UC)
• PI in VOLGA Phase III Trial: “A Phase I Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)”
• PI in SUNRISE-1 Phase Ilb Trial: “Phase 26 Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab, TAR-200 CalmetteGuerin (BCG) who are Ineligible for or Elected Not to Undergo Radical Cystectomy”
• PI in SUNRISE-2 Phase III Trial: “A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder who are not Receiving Radical Cystectomy”
• PI in PROOF-302 Phase I Trial: “A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations”
• PI in CONTACT-02 Phase III Trial: “A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer”
•  
• PI in JAVELIN Bladder Medley Phase I Trial: “A Phase I, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination with Other Anti-Tumor Agents as a Maintenance Treatment in Participants with Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress with First Line Platinum-Containing Chemotherapy”
• PI in KEYNOTE-B15 Phase I Trial: “A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin- eligible Participants with Muscle-Invasive Bladder Cancer”
• PI in MK-6482-011 Phase 3 Trial: “An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Treatment in Participants with Advanced Renal Cel Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy”
• PI in BO44157 Phase I Trial: “A Phase I, Randomized, Multicenter, Open- Label, Controlled Study Of R07247669 Alone Or In Combination With Tiragolumab Versus Atezolizumab In Patients With Previously Untreated Locally Advanced Or Metastatic Urothelial Cancer Who Are Ineligible For Platinum-Containing Chemotherapy”
• 06/11/2023:GPC online training certification

• Coordinator: Hellenic Cooperative Oncology Group (HeCOG)- Immuno- Oncology Working Group
• Coordinator: Hellenic Cooperative Oncology Group (HeCOG)- Genitourinary Oncology Working Group
• Member of the Cancer Guidelines Committee of the Hellenic Society of Medical Oncology (Section of Gynecologic Cancers)
• Member of the “Cancer Treatment Communications” Editorial Board
• Member of the “Journal of Immunotherapeutic Applications” Editorial Board
• Member of the Helenic Society of Medical Oncology, European Society for Medical Oncology, American Society of Clinical Oncology